Paul Herendeen Buys 10,000 Shares of Elanco Animal Health (NYSE:ELAN) Stock

Elanco Animal Health Incorporated (NYSE:ELAN) Director Paul Herendeen acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $23.68 per share, for a total transaction of $236,800.00. Following the completion of the transaction, the director directly owned 111,687 shares in the company, valued at approximately $2,644,748.16. This represents a 9.83% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Elanco Animal Health Price Performance

Shares of NYSE ELAN opened at $22.73 on Wednesday. The company has a current ratio of 2.05, a quick ratio of 1.10 and a debt-to-equity ratio of 0.58. The company’s 50-day moving average price is $24.65 and its 200 day moving average price is $24.06. Elanco Animal Health Incorporated has a 52 week low of $17.08 and a 52 week high of $27.98. The stock has a market cap of $11.36 billion, a price-to-earnings ratio of -55.44, a PEG ratio of 1.33 and a beta of 1.67.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. During the same quarter in the previous year, the business posted $0.26 earnings per share. The firm’s quarterly revenue was up 10.2% compared to the same quarter last year. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, research analysts forecast that Elanco Animal Health Incorporated will post 1.12 earnings per share for the current fiscal year.

Institutional Trading of Elanco Animal Health

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC raised its position in Elanco Animal Health by 5.9% in the fourth quarter. Parallel Advisors LLC now owns 7,060 shares of the company’s stock worth $160,000 after acquiring an additional 392 shares in the last quarter. Sapient Capital LLC boosted its position in shares of Elanco Animal Health by 0.3% during the 2nd quarter. Sapient Capital LLC now owns 128,573 shares of the company’s stock valued at $3,164,000 after purchasing an additional 420 shares in the last quarter. Lazard Asset Management LLC grew its stake in shares of Elanco Animal Health by 0.6% in the 4th quarter. Lazard Asset Management LLC now owns 72,065 shares of the company’s stock worth $1,631,000 after purchasing an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC grew its stake in shares of Elanco Animal Health by 0.4% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company’s stock worth $2,516,000 after purchasing an additional 428 shares during the last quarter. Finally, Meeder Advisory Services Inc. raised its holdings in shares of Elanco Animal Health by 4.8% in the 4th quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company’s stock worth $254,000 after purchasing an additional 510 shares in the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ELAN has been the topic of a number of recent research reports. JPMorgan Chase & Co. upped their target price on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research note on Thursday, May 7th. Morgan Stanley boosted their price target on Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. TD Cowen upped their price objective on Elanco Animal Health from $31.00 to $32.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Wall Street Zen lowered Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research note on Sunday, May 24th. Finally, UBS Group lifted their price objective on Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health has an average rating of “Moderate Buy” and a consensus target price of $29.09.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.